Summary of Key Points Core Viewpoint - The company, Sichuan Hongda Co., Ltd., is utilizing the raised funds through agreed deposits and notice deposits to enhance fund efficiency and shareholder returns while ensuring the safety and liquidity of the funds [1][2][5]. Fundraising Basic Information - The company has issued 609,600,000 shares at a price of RMB 4.68 per share, raising a total of RMB 2,834,758,430.19, verified by Sichuan Huaxin Accounting Firm [1][2]. Fund Usage - The total amount raised is RMB 285,292.80 million, with RMB 134,751.11 million allocated for debt repayment and RMB 150,541.69 million for working capital [2]. Fund Storage Method - The company will store the remaining funds (RMB 283,536.92 million) in agreed deposits and notice deposits to improve fund utilization efficiency while maintaining liquidity [2][3]. Risk Control Measures - The company has established a fund management system to ensure the effective and compliant operation of fund storage, with independent directors and supervisory boards having the authority to oversee fund usage [4]. Impact on the Company - The decision to store funds in agreed and notice deposits will not affect the normal use of the raised funds and is expected to enhance fund returns and overall company performance [4]. Review Procedures - Both the board of directors and the supervisory board have approved the storage method, confirming compliance with relevant regulations and ensuring no adverse impact on shareholder interests [4][5].

Group 1 - The company, Sichuan Hongda Co., Ltd., has raised a total of RMB 2,834,758,430.19 through the issuance of 609,600,000 shares at a price of RMB 4.68 per share, as approved by the China Securities Regulatory Commission [1] - The raised funds will be used to repay debts amounting to RMB 134,751.11 million and to supplement working capital with RMB 150,541.69 million [2] - The company has pre-invested RMB 96,541.50 million of its own funds to address debt issues before the raised funds were available, which it plans to replace with the raised funds [2][3] Group 2 - The total issuance costs amount to RMB 1,816.96 million, of which RMB 52.36 million has been paid using self-raised funds, and this amount will also be replaced with the raised funds [2] - The board of directors and the supervisory board have approved the use of raised funds to replace pre-invested self-raised funds, confirming compliance with relevant regulations [4] - The sponsor, CITIC Securities, has verified that the company’s actions comply with legal requirements and do not harm shareholder interests [4]

Summary of Key Points Core Viewpoint The report outlines the fundraising activities and the actual usage of funds by Shandong Xinchao Energy Co., Ltd. as of December 31, 2024, highlighting the total amount raised, the allocation of funds, and the management practices in place to ensure compliance with regulatory requirements. Group 1: Fundraising Overview - The company raised a total of RMB 2,099,999,974.86 through a non-public offering of 206,084,394 shares at RMB 10.19 per share, with a net amount of RMB 2,044,204,730.26 after deducting issuance costs [1][2] - As of December 31, 2024, the total amount used from the raised funds was RMB 1,553,953,785.42, with specific allocations for intermediary fees and operational funds for oilfield assets [2][3] Group 2: Fund Management Practices - The company has established a management system for fundraising that includes special account storage and strict approval procedures to ensure funds are used for their intended purposes [3][4] - Independent directors have the authority to inspect the usage of funds and can hire accounting firms for special audits [3] Group 3: Fund Usage Details - The company has utilized RMB 60 million for intermediary fees in 2016 and has allocated funds for operational costs related to Howard and Borden oilfield assets in subsequent years [2][5] - As of the end of 2024, the remaining balance of unused funds was RMB 655,775,150.75, with RMB 5,775,150.75 in special accounts [10][11] Group 4: Changes in Fund Usage - The company has made adjustments to the intended use of funds, reallocating amounts to enhance efficiency and returns, particularly for the Howard and Borden oilfield assets [7][8] - The company has also temporarily supplemented working capital with raised funds, which has not yet been fully returned to the designated accounts [8][9] Group 5: Audit and Compliance - The report has been audited by Lixin Accounting Firm, which confirmed that the fundraising and usage report complies with relevant regulations [6][9] - The independent financial advisor, Caitong Securities, noted that the company failed to return temporarily supplemented funds as required, and will continue to monitor the situation [9]

证券代码：688626 证券简称：翔宇医疗 公告编号：2025-040 河南翔宇医疗设备股份有限公司 关于开立募集资金专项账户并签订募集资金专户存 储四方监管协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 根据中国证券监督管理委员会于 2021 年 1 月 26 日出具的《关于同意河南翔 宇医疗设备股份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕254 号），河南翔宇医疗设备股份有限公司（以下简称"公司"）获准向社会公众发 行人民币普通股（A 股）40,000,000 股，每股发行价格为人民币 28.82 元，本次 发行募集资金总额 1,152,800,000.00 元；扣除发行费用后，募集资金净额为 上述募集资金已全部到账，并经立信会计师事务所（特殊普通合伙）审验， 并于 2021 年 3 月 26 日出具了信会师报字2021第 ZE10046 号的《验资报告》。 公司依照规定对上述募集资金进行专户存储管理，并与保荐机构、募集资金专户 监管银行签订了募集资金专户存储监管协议 ...

● 现金管理种类：华夏银行包头分行结构性存款 ● 现金管理金额：2,100 万元 证券代码：603185 证券简称：弘元绿能 公告编号：2025-031 弘元绿色能源股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 已履行的审议程序：弘元绿色能源股份有限公司（以下简称"公司"） 于 2025 年 5 月 20 日召开 2024 年年度股东大会，审议并通过了《关于使用闲置 募集资金进行现金管理的议案》，同意公司在不影响公司募投项目建设和正常经 营业务的前提下，使用总额不超过人民币 38,000 万元（含）的闲置募集资金进 行现金管理，适当购买安全性高、流动性好、有保本约定的理财产品或存款类产 品，投资产品的期限不超过 12 个月，在上述额度内，资金可循环滚动使用。公 司监事会、保荐机构均发表了同意意见。 ● 特别风险提示：公司本次使用暂时闲置的募集资金进行现金管理，投资 的产品为安全性高、流动性好、有保本约定的理财产品，但金融市场可能受宏观 经济的影响，不排除本次现金管理受到市场波动影响预期 ...

的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603382 证券简称：海阳科技 公告编号：2025-009 海阳科技股份有限公司 关于使用部分暂时闲置募集资金进行现金管理 ? 本次现金管理产品：大额存单。 ? 本次现金管理金额：人民币 20,000 万元。 ? 已履行的审议程序：海阳科技股份有限公司（以下简称"公司"）于 2025 年 6 月 27 日召开第二届董事会第十六次会议和第二届监事会第十二次会议，分 别审议通过了《关于使用部分闲置募集资金进行现金管理的议案》，同意公司及 子公司使用不超过人民币 22,000 万元（包含本数）的部分暂时闲置募集资金进 行现金管理，使用期限不超过 12 个月，自公司董事会审议通过之日起 12 个月之 内有效。前述额度和期限范围内，资金可循环滚动使用。保荐机构出具了同意的 核查意见，本事项无需提交股东大会审议。具体内容详见公司 2025 年 6 月 30 日披露于上海证券交易所网站（www.sse.com.cn）的《海阳科技股份有限公司关 于使用部分 ...

Summary of Key Points Core Viewpoint The company, Saiwei Times Technology Co., Ltd., is adjusting its fundraising project investment amounts, internal structure, and the use of excess funds to enhance the efficiency of fund utilization and align with its strategic goals [2][24]. Group 1: Fundraising Overview - The company raised a net amount of approximately 723.1 million yuan from its initial public offering, with all funds received by July 7, 2023 [2][5]. - As of May 31, 2025, the total unused fundraising amount is approximately 289.8 million yuan, which includes idle funds and financial products [5][18]. Group 2: Project Investment Adjustments - The company plans to adjust the investment amounts and internal structure of its fundraising projects, reallocating a total of 70 million yuan to "Brand Building and Channel Promotion" and "Logistics and Warehousing Upgrade" projects [6][10]. - The total investment for the "Brand Building and Channel Promotion" project will increase from approximately 87.7 million yuan to 228.3 million yuan [12][17]. Group 3: Implementation and Strategic Rationale - The adjustments are aimed at enhancing brand awareness and customer loyalty through diversified marketing channels, including online advertising and social media collaborations [11][17]. - The company emphasizes the necessity of these adjustments to maintain competitiveness in the fashion industry and to support its long-term growth strategy [18][24]. Group 4: Changes in Project Implementation Entities - The company is adding new implementation entities for its projects, including subsidiaries in Hong Kong and Shenzhen, to better integrate resources and expand its market reach [20][23]. - The adjustments will not change the total investment amount for the projects and are designed to optimize resource allocation [19][24]. Group 5: Regulatory Compliance and Oversight - The adjustments have been approved by the company's board and supervisory committee, ensuring compliance with relevant regulations and protecting shareholder interests [22][24]. - The company will open dedicated fundraising accounts for the new project entities and will implement strict oversight measures to ensure proper fund management [21][24].

Core Viewpoint - The company intends to temporarily use part of its idle raised funds to supplement working capital, ensuring that this does not affect the normal progress of its fundraising investment projects [6][9]. Group 1: Fundraising Overview - The company was approved to publicly issue 70.6 million shares at a price of RMB 13.39 per share, raising a total of RMB 945.334 million, with a net amount of RMB 843.209 million after deducting issuance costs [2][3]. - As of the date of the verification opinion, the remaining balance of the raised funds is RMB 192.519 million, including oversubscription funds [6]. Group 2: Fund Utilization - The company has used RMB 496.663 million of the raised funds for third-party medical device logistics construction projects [4]. - The company plans to use up to RMB 92.75 million of idle raised funds temporarily to supplement working capital, with a usage period not exceeding 12 months [7][9]. Group 3: Approval and Oversight - The board of directors and the supervisory board have approved the use of idle funds, ensuring compliance with relevant regulations [9][10]. - The company will open a special account at a bank for the management of these funds and sign a tripartite supervision agreement to oversee the storage and usage of the raised funds [8]. Group 4: Financial Efficiency - By utilizing the idle funds, the company expects to save approximately RMB 2.78 million in financial costs based on the current loan market rate of 3.00% [8].

Core Viewpoint - The company has approved the use of temporarily idle raised funds for cash management to enhance the efficiency of fundraising while ensuring the safety of the funds [1][3]. Group 1: Cash Management Approval - The company agreed to use up to RMB 50 million of temporarily idle raised funds for cash management, which can be recycled within twelve months from the board's approval date [1]. - The decision was made during the fifth board meeting and the fourth supervisory meeting held on September 12, 2024 [1]. Group 2: Investment Details - The company has subscribed to structured deposits with the Bank of China, with a total investment amount of RMB 2,000 million in various products [2][6]. - The expected annualized return for the structured deposits ranges from 2.63% to 2.80% [5][6]. Group 3: Impact on Company Operations - The cash management activities will not affect the normal operation of fundraising investment projects or the company's main business [3][4]. - The company aims to achieve certain investment returns while safeguarding shareholder interests [3].

Summary of Key Points Core Viewpoint The company, Kailaiying Pharmaceutical Group (Tianjin) Co., Ltd., is undergoing changes in the use of raised funds, including new investment projects, adjustments in investment amounts, and delays in project timelines, to enhance operational efficiency and align with market opportunities. Group 1: Fundraising Overview - The company raised a total of RMB 2,277,875,164.30 from a non-public stock issuance, with a net amount of RMB 2,274,960,656.06 after deducting issuance costs [1][2] - The funds are stored in a dedicated account, regulated by a tripartite agreement among the company, the sponsor, and the bank [2] Group 2: Fund Usage Status - As of June 30, 2025, the company has allocated funds to various projects, including the expansion of its life sciences platform and the construction of a biopharmaceutical R&D base [3][4] - The total investment for the projects is RMB 228,070.62 million, with cumulative investments of RMB 163,909.18 million [4] Group 3: Changes in Fund Usage - The company has proposed to change the use of funds for the "Taixing Project" and redirect remaining funds to new projects, including a chemical macromolecule project and a high-end formulation project [5][6] - The investment amount for the Taixing Project will be reduced by RMB 400 million, with the remaining funds allocated to new projects [6][11] Group 4: New Investment Projects - A new project, the "Chemical Macromolecule Integration Project," will receive RMB 47,367.72 million from the remaining funds, with a total investment of RMB 50,800.00 million [11][12] - The project aims to enhance the company's capacity in the CDMO field and is expected to take 48 months to complete [12][14] Group 5: Financial Performance - The company's total assets as of December 31, 2024, were RMB 3,073,514,644.17, with total liabilities of RMB 2,080,120,300.01 and net assets of RMB 993,394,344.16 [13] - The company reported a revenue of RMB 1,597,172,881.12 and a net profit of RMB 52,163,151.56 for the same period [13] Group 6: Strategic Implications - The changes in fund usage are aligned with the company's long-term strategic planning and are expected to improve operational efficiency and competitiveness [19][20] - The company aims to leverage market trends and enhance its capabilities in innovative drug development, particularly in the chemical macromolecule sector [15][16]